Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-BN-EBV Vaccine in Healthy Young Adults
NCT07888088Phase 1Not yet recruiting
- Sponsor
- Bavarian Nordic
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Epstein-Barr virus infection comparing MVA-BN-EBV with Placebo (2 arms). Primary endpoints: Serious Adverse Events at 8 weeks, Grade 3 or higher Adverse Events related to trial vaccine at 8 days and 3 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
MVA-BN-EBV
03
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT07888088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07888088.